Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, S-1, W-16, Chuoku, Sapporo, Hokkaido, 060-8543, Japan.
Division of Gastroenterology, Department of Medicine, Iwate Medical University, Morioka, Japan.
J Gastroenterol. 2022 Mar;57(3):174-184. doi: 10.1007/s00535-022-01851-1. Epub 2022 Jan 28.
The spread of coronavirus disease 2019 (COVID-19) had a major impact on the health of people worldwide. The clinical background and clinical course of inflammatory bowel disease (IBD) among Japanese patients with COVID-19 remains unclear.
This study is an observational cohort of Japanese IBD patients diagnosed with COVID-19. Data on age, sex, IBD (classification, treatment, and activity), COVID-19 symptoms and severity, and treatment of COVID-19 were analyzed.
From 72 participating facilities in Japan, 187 patients were registered from June 2020 to October 2021. The estimated incidence of COVID19 in Japanese IBD patients was 0.61%. The majority of IBD patients with COVID-19 (73%) were in clinical remission. According to the WHO classification regarding COVID-19 severity, 93% (172/184) of IBD patients had non-severe episodes, while 7% (12/184) were severe cases including serious conditions. 90.9% (165/187) of IBD patients with COVID-19 had no change in IBD disease activity. A logistic regression analysis stepwise method revealed that older age, higher body mass index (BMI), and steroid use were independent risk factors for COVID-19 severity. Six of nine patients who had COVID-19 after vaccination were receiving anti-tumor necrosis factor (TNF)-α antibodies.
Age, BMI and steroid use were associated with COVID-19 severity in Japanese IBD patients.
2019 年冠状病毒病（COVID-19）的传播对全球人民的健康产生了重大影响。日本 COVID-19 患者炎症性肠病（IBD）的临床背景和临床过程尚不清楚。
本研究是一项针对日本 IBD 患者 COVID-19 的观察性队列研究。分析了年龄、性别、IBD（分类、治疗和活动）、COVID-19 症状和严重程度以及 COVID-19 治疗的数据。
从日本的 72 家参与机构中，于 2020 年 6 月至 2021 年 10 月登记了 187 例患者。日本 IBD 患者 COVID-19 的估计发病率为 0.61%。大多数患有 COVID-19 的 IBD 患者（73%）处于临床缓解期。根据 COVID-19 严重程度的世界卫生组织分类，93%（172/184）的 IBD 患者为非重症病例，而 7%（12/184）为重症病例，包括严重情况。90.9%（165/187）的 COVID-19 合并 IBD 患者的 IBD 疾病活动无变化。逐步逻辑回归分析显示，年龄较大、体重指数（BMI）较高和使用类固醇是 COVID-19 严重程度的独立危险因素。在接种疫苗后发生 COVID-19 的 9 例患者中，有 6 例正在接受抗肿瘤坏死因子（TNF）-α 抗体治疗。
年龄、BMI 和类固醇的使用与日本 IBD 患者 COVID-19 的严重程度相关。
